Next generation KRAS inhibitor divarasib significantly extends lung cancer survival
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.
Read original article on The Medical News →Related news
-
One in three young adults turns to AI for substance use
United Kingdom
-
Geriatric chronic kidney disease patients benefit from SGLT2 inhibition
United Kingdom
-
Airborne ESKAPE bacteria pose severe risks to immunocompromised patients
United Kingdom
-
Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA
United Kingdom
-
Substance use driving increases in emergency department visits, hospitalizations for young mothers
United Kingdom
-
A simple liquid can stop cavities without drilling, major study confirms
United States
-
Can happy feelings trigger eating too? Researchers explored both sides of emotional eating
United Kingdom
-
Beer, wine or spirits: A large study finds different mortality patterns for each
United Kingdom